Four Directors at Insmed Inc sold/sold after exercising options 42,348 shares at between 68.720USD and 70.181USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The independent financial analyst theScreener just lowered the general evaluation of INSMED (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date March 15, 2022, the closing price was USD 21.79 and its target price was estim...
Bullish Outlook Intact; Mild Concerns Subside The action we are seeing in broad indexes, Sectors, and in market dynamics continues to support our overall bullish outlook. Additionally, the mild deterioration in market dynamics that we discussed the past two weeks is now much less of a concern. Continue to buy dips. · S&P 500. The major averages are hitting new all-time highs; and new highs are bullish. Key support levels we are watching on the S&P 500 include short-term support at 3870...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BRIDGEWATER, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their ...
Insmed Announces Changes to its Board of Directors —Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director— —Donald Hayden, Jr. Steps Down as Chairman After 13 Years of Distinguished Service— —Chief Executive Officer Will Lewis Elected Chairman of the Board— —David Brennan Elected Lead Independent Director— BRIDGEWATER, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced several changes to its board of d...
Insmed to Present at Three November Conferences BRIDGEWATER, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following investor conferences: The Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:20 a.m. MST.The Stifel 2018 Healthcare Conference in New York, NY on Wednesday, November 14, 2018 at 12:30 p.m. ET.The Evercore ISI HealthconX Confer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.